Exparel and Education to Avoid Opioids After Carpal Tunnel Release
Launched by KETTERING HEALTH NETWORK · Mar 7, 2019
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help people recover from carpal tunnel surgery without using opioids, which are strong pain medications that can lead to dependence. The study is testing a long-lasting local anesthetic called Exparel, combined with education about avoiding opioids, and comparing it to a standard treatment that uses a different local anesthetic and allows for opioid use. This research aims to see if using Exparel can effectively manage pain after surgery while reducing the need for opioids.
To be part of this study, participants need to be at least 18 years old and have been diagnosed with carpal tunnel syndrome, which can cause pain and numbness in the hand. However, those who have used opioids in the past six months or have allergies to certain medications will not be eligible. If you join the trial, you will receive specific instructions and support regarding pain management after your surgery. This study is currently recruiting participants of all genders aged between 18 and 74.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • carpal tunnel syndrome diagnosed either by physical exam or EMG
- • age \>18.
- Exclusion Criteria:
- • allergy to bupivacaine
- • pre-operative opioid usage within the last six months
- • patients allergic to Percocet or acetaminophen
- • patients taking tricyclic antidepressants (interaction with bupivacaine)
- • vulnerable populations (prisoners or pregnant women)
About Kettering Health Network
Kettering Health Network is a comprehensive healthcare system dedicated to enhancing the health and well-being of the communities it serves through innovative clinical research and patient-centered care. With a commitment to advancing medical knowledge and improving treatment outcomes, Kettering Health Network engages in a wide range of clinical trials across various therapeutic areas. The organization combines state-of-the-art facilities, a multidisciplinary team of experienced professionals, and a patient-centric approach to ensure the highest standards of safety and efficacy in its research endeavors. By fostering collaboration between researchers, healthcare providers, and patients, Kettering Health Network aims to translate cutting-edge research into meaningful healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dayton, Ohio, United States
Patients applied
Trial Officials
Ronald Buczek, DO
Principal Investigator
Kettering Health Network
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials